LONG-TERM FOLLOW-UP OF VITRECTOMY FOR DIFFUSE NONTRACTIONAL DIABETIC MACULAR EDEMA

Retina ◽  
2009 ◽  
Vol 29 (4) ◽  
pp. 464-472 ◽  
Author(s):  
KAZUYUKI KUMAGAI ◽  
MARIKO FURUKAWA ◽  
NOBUCHIKA OGINO ◽  
ERIC LARSON ◽  
MASAYOSHI IWAKI ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Long Term Follow Up

Long-term follow-up of diabetic macular edema treated with dexamethasone implant: a real-life study

2020 ◽  
Vol 57 (12) ◽  
pp. 1413-1421 ◽  
Author(s):  
Thibaud Mathis ◽  
Théo Lereuil ◽  
Amro Abukashabah ◽  
Nicolas Voirin ◽  
Aditya Sudhalkar ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
Dexamethasone Implant ◽  
Life Study ◽  
Long Term Follow Up ◽  
Real Life Study

Long-term Follow-up Results of Pars Plana Vitrectomy for Diabetic Macular Edema

2007 ◽  
Vol 51 (4) ◽  
pp. 285-291 ◽  
Author(s):  
Teiko Yamamoto ◽  
Shinobu Takeuchi ◽  
Yukihiro Sato ◽  
Hidetoshi Yamashita
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Pars Plana Vitrectomy ◽  
Long Term Follow Up ◽  
Pars Plana

scholarly journals Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers

2018 ◽  
Vol 2018 ◽  
pp. 1-11
Author(s):  
Birgit Weingessel ◽  
Kata Miháltz ◽  
Andreas Gleiss ◽  
Florian Sulzbacher ◽  
Christopher Schütze ◽  
...  
Keyword(s):  
Growth Factor ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Morphological Characteristics ◽  
Antivascular Endothelial Growth Factor ◽  
Long Term Follow Up ◽  
Endothelial Growth Factor ◽  
Deferred Group

Purpose. Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal antivascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics. Methods. Prospective clinical trial (50 treatment-naive eyes) with DME randomized 1 : 1 receiving intravitreal ranibizumab (0.5 mg/0.05 ml) and prompt grid laser compared with ranibizumab and deferred laser. Morphological characteristics potentially relevant for prognosis were assessed at baseline, month 6, month 9, and years 1, 2, 3, 4, and 5 of follow-up. Results. Although functional results were slightly higher in the prompt group at week 12 (0.5; 20/40 Snellen (SD = 0.04, 0.3 logMAR) versus 0.4; 20/50 Snellen (SD = 0.04, logMAR: 0.4), p=0.4) and month 9 (prompt group: 0.5; 20/40 Snellen (SD = 0.03, 0.3 logMAR) versus deferred group: 0.4; 20/50 Snellen (SD = 0.04, 0.4 logMAR), p=0.4), these were statistically insignificant. There was no significant benefit regarding functionality during long-term follow-up in the prompt group compared to the deferred group. BCVA in the eyes with clusters of hyperreflective foci in the central macular region was inferior compared with the eyes without these alterations at year 5 (0.39; 20/50 Snellen, (SD = 0.25, 0.4 logMAR) versus 0.63; 20/80 Snellen (SD = 0.22, 0.2 logMAR), p<0.01). Conclusion. Grid laser and ranibizumab therapy are effective in DME management during the long-term follow-up. Intraretinal hyperreflective material in SD-OCT is negatively related to BCVA.

LONG-TERM FOLLOW-UP OF INFLAMMATORY CYSTOID MACULAR EDEMA

Retina ◽  
2012 ◽  
Vol 32 (8) ◽  
pp. 1624-1628 ◽  
Author(s):  
Paris G. Tranos ◽  
Konstantinos T. Tsaousis ◽  
Athanasios N. Vakalis ◽  
Solon Asteriades ◽  
Carlos E. Pavesio
Keyword(s):  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Long Term Follow Up

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion

2009 ◽  
Vol 247 (12) ◽  
pp. 1635-1641 ◽  
Author(s):  
Alexandra E. Hoeh ◽  
Thomas Ach ◽  
Karen B. Schaal ◽  
Alexander F. Scheuerle ◽  
Stefan Dithmar
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Bevacizumab Treatment ◽  
Long Term Follow Up

Long-Term Follow-Up of Oral Administration of Flavonoids, Centella asiatica and Melilotus, for Diabetic Cystoid Macular Edema Without Macular Thickening

2013 ◽  
Vol 29 (8) ◽  
pp. 733-737 ◽  
Author(s):  
Raimondo Forte ◽  
Gilda Cennamo ◽  
Paola Bonavolontà ◽  
Arduino Pascotto ◽  
Giuseppe de Crecchio ◽  
...  
Keyword(s):  
Oral Administration ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Centella Asiatica ◽  
Long Term Follow Up

Evaluation of Macular Changes in Long Term Period Following Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Diabetic Macular Edema

2021 ◽  
Author(s):  
Betul Onal Gunay ◽  
Gurkan Erdogan
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Pars Plana Vitrectomy ◽  
Internal Limiting Membrane ◽  
Additional Treatment ◽  
Final Visit ◽  
Ilm Peeling ◽  
Pars Plana

Aim: To evaluate long term macular changes following pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling for diabetic macular edema (DME) Methods: Forty eligible eyes of 37 patients were included in this retrospective study. Best corrected visual acuity (BCVA), central macular thickness (CMT) and 5-mm macular volume (5-MV) were examined preoperatively and at postoperative 1st, 2nd, 3rd, 6th, 12th, 24th months and final visits. Response to surgical treatment was considered as recurrence, reincrease and recovery of DME based on macular changes. Results: Mean follow-up time was 51.1±19.0 months following surgery. Recurrence (n=5) and reincrease (n=17) of DME was observed in 22 eyes (55%) and additional treatments were applied. Recovery of DME was observed in 18 eyes (45%). Preoperative and final visit mean BCVAs (logMAR) were 1.08±0.37 and 0.93±0.45, respectively (p=0.02). Preoperative and final visit mean CMTs were 514.74±155.65 µm and 281.87±112.58 µm, respectively (p<0.001). The 5-MV significantly decreased following surgery (8.18±1.57 mm3 to 6.52±1.39 mm3) (p<0.001). DME was present in 12 eyes (%30) at final visit. Conclusion: Although PPV with ILM peeling had an efficacy in DME management, this effect tends to decrease over time such that considerable amount of patients required additional treatment.

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

2015 ◽  
Vol 254 (5) ◽  
pp. 835-844 ◽  
Author(s):  
Tom Kornhauser ◽  
Roy Schwartz ◽  
Michaella Goldstein ◽  
Meira Neudorfer ◽  
Anat Loewenstein ◽  
...  
Keyword(s):  
Macular Edema ◽  
Bevacizumab Treatment ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document